Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 1 · 33.3%High 0 · 0%

One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo

Adverse events up to week 12 · Patients with active Crohn's disease

One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.91 [0.75, 1.09]
1 study · 131 participants
Moderate

One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo

Serious adverse events up to week 12 · Patients with active Crohn's disease

One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.93 [0.34, 2.49]
1 study · 131 participants
Low

One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.46 [0.04, 4.98]
1 study · 131 participants
Low